1. Surveillance of resistance in bacteria causing community‐acquired respiratory tract infections 
D. Felmingham, C. Feldman, W. Hryniewicz, K. Klugman, S. Kohno, D.E. Low, C. Mendes, A.C. Rodloff 
Clinical Microbiology and Infection 
Volume 8, Pages (January 2002)
DOI: /j s.2.5.x
Copyright © 2002 European Society of Clinical Infectious Diseases Terms and Conditions

2. Figure 1
Prevalence of penicillin nonsusceptibility in Streptococcus pneumoniae across the world (various sources, data correct up to February 2001).
Clinical Microbiology and Infection 2002 8, 12-42DOI: ( /j s.2.5.x)
Copyright © 2002 European Society of Clinical Infectious Diseases Terms and Conditions

3. Figure 2
Consumption of βlactam (A) and macrolide (B) antibiotics in Central and Eastern European countries (various sources). Abbreviations: AMP=ampicillin; AMX=amoxicillin; AMX/CLAV=amoxicillin–clavulanate; AZI=azithromycin; CLA=clarithromycin; CLIN=clindamycin; DDD=defined daily doses; ERY=erythromycin; LINC=lincomycin; PEN G=penicillin G (benzylpenicillin); PEN V=penicillin V (phenoxymethylpenicillin); SPIR=spiramycin.
Clinical Microbiology and Infection 2002 8, 12-42DOI: ( /j s.2.5.x)
Copyright © 2002 European Society of Clinical Infectious Diseases Terms and Conditions

4. Figure 3
Prevalence of nonsusceptibility to penicillin (PEN), erythromycin (ERY) and tetracycline (TET) among Streptococcus pneumoniae isolates from Asian countries participating in PROTEKT [56].
Clinical Microbiology and Infection 2002 8, 12-42DOI: ( /j s.2.5.x)
Copyright © 2002 European Society of Clinical Infectious Diseases Terms and Conditions

5. Figure 4
Changes in penicillin and macrolide‐resistance prevalence in respiratory Streptococcus pneumoniae isolates in South Africa [21,86].
Clinical Microbiology and Infection 2002 8, 12-42DOI: ( /j s.2.5.x)
Copyright © 2002 European Society of Clinical Infectious Diseases Terms and Conditions